Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-12
2011-04-12
Rawlings, Stephen L (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100
Reexamination Certificate
active
07923538
ABSTRACT:
The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
REFERENCES:
patent: 6737056 (2004-05-01), Presta
patent: 7297775 (2007-11-01), Idusogie et al.
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2005/0208519 (2005-09-01), Liew et al.
patent: 2007/0111281 (2007-05-01), Sondermann et al.
patent: 1443961 (2004-08-01), None
patent: 02/056910 (2002-07-01), None
patent: 03-035835 (2003-05-01), None
patent: 2006-020114 (2006-02-01), None
Kabat, et al. Sequences of proteins of immunological interest. 1987. 4thedition. pp. 307-308.
Tao, M., Smith, R.I.F., and Morrison, S.L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. Journal of Experimental Medicine, 1993. vol. 178, pp. 661-667.
Shinkawa, Nakamura, Yamane, Shoji-Hosaka, Kanda, Sakurada, Uchida, Anazawa, Satoh, Yamasaki, Hanai, and Shitara. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing ADCC. Journal of Biological Chemistry, 2003. vol. 278, p. 3466-73.
Kushihata, F., Watanabe, J., Mulder, A., Claas, F., and Scornik, J.C. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential. Transplantation, 2004. vol. 78, pp. 995-1001.
Norderhaug, L., Brekke, O.H., Bremnes, B., Sandin, R., Aase, A., Michaelsen, T.E., and Sandlie, I. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge. European Journal of Immunology, 1991. vol. 21, pp. 2379-2384.
Michaelsen, T.E., Aase, A., Westby, C., and Sandlie, I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scandinavian Journal of Immunology, 1990. vol. 32, pp. 517-528.
Amaral et al (Biosep., 10:139-143, 2002).
Teeling et al (Blood, 104:1793-1800, 2004).
Brekke O.H et al., Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis, Mol. Immunol., 1993, vol. 30, p. 1419-1425.
Yamane-Ohnuki N. et al., Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhancedantiboby-dependent cellular cytotoxicity, Biotechnol. Bioeng., 2004, vol. 87, p. 614-622.
Akira Okazaki et al., “Fucose Kesshitsu ni yoru Kotai Efector Kassei no Kojo”, Seikagaku, 2005 Nen, 1 GAtsu, vol. 77, pp. 45 to 50.
Robert L. Shields, et al.; “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity”; May 2002; Journal of Biological Chemistry; pp. 26733-26740; vol. 277, No. 30.
Niwa, Rinpei et al. “Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 is Independent of FcγRIIIa Functional Polymorphism”, Clinical Cancer Research, The American Association for Cancer Research, 2004, 10(18): 6248-6255. XP002354666.
Medesan, Corneliu et al. “Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1”, Journal of Immunology, 1997, 158(5): 2211-2217. XP002532767.
Natsume Akito
Niwa Rinpei
Shitara Kenya
Duffy Brad
Kyowa Hakko Kirin Co., Ltd
Rawlings Stephen L
Sughrue & Mion, PLLC
LandOfFree
Recombinant antibody composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibody composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibody composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699114